Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T

NCT05617651 | Unknown Phase 1 DMC

• 1 other identifier: DTC22-IP018
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This study evaluate the pharmacokinetic and safety of IY-NT-T in healthy adults

Conditions

Pharmacokinetics

Keywords

proton pump inhibitor

Outcome Measures

Primary Outcomes (2)

• Ilaprazole AUCt

  ilaprazole AUCt(Area under the concentration-time curve)

  Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour

• Ilaprazole Cmax

  ilaprazole Cmax(Maximum concentration of drug in plasma)

  Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour

Secondary Outcomes (5)

• Ilaprazole AUC∞

  Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour

• Ilaprazole tmax

  Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour

• Ilaprazole t1/2

  Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour

• Ilaprazole tmax-tlag

  Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour

• Ilaprazole intra-subject tlag difference

  Predose(0hour), after dose 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 32, 34, 36, 40, 48 hour

Study Arms (2)

A group

ACTIVE COMPARATOR

Period 1 : Ilaprazole 10mg 2Tab, one a day Period 2 : Ilaprazole 20mg 1Tab, one a day Period 3 : Ilaprazole 10mg 2Tab, one a day

Drug: IY-NT-T; Drug: IY-NT-R

B group

ACTIVE COMPARATOR

Period 1 : Ilaprazole 20mg 1Tab, one a day Period 2 : Ilaprazole 10mg 2Tab, one a day Period 3 : Ilaprazole 20mg 1Tab, one a day

Drug: IY-NT-T; Drug: IY-NT-R

Interventions

IY-NT-T DRUG

Ilaprazole 20mg

A group; B group

IY-NT-R DRUG

Ilaprazole 10mg

Also known as: Noltec(the brand name)

A group; B group

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Volunteers aged 19 years and above at screening
• A volunteer who weighs ≥ 50kg (≥ 45kg for women) and has a body mass index(BMI)\* of ≥18.0 and ≤ 30 at screening
• \*BMI(body mass index, kg/m\^2)= Body weight (kg)/\[height (m)\^2\]
• A volunteer who has no congenital or chronic diseases, no pathological symptoms, or findings from medical examination at screening
• A volunteer who is determined by the principal investigator or sub-investigator(responsible physician) as eligible as a subject based on diagnostic tests( hematology, hematochemical, serum, urinalysis) and electrocardiogram tests established and conducted according to the characteristics of the study drug
• A volunteer and their spouse or partner, who agree to use a medically appropriate method of contraception to exclude potential of pregnancy and not to provide sperm or ova from the first dose to 7 days after the last dose of study drug
• \* Contraception methods: Intrauterine device, vasectomy, tubal ligation and contraceptive barrier methods (male condoms, women condoms, cervical caps. Contraceptive diaphragm, sponge,etc) used in combination or if spermicide is used, two or more contraceptive barrier methods
• A volunteer who voluntarily provided written consent to participation in the entire study process after being fully informed of the study objective, contents, characteristics of the study drugs, and expected adverse reactions, prior to study participation

You may not qualify if:

• A volunteer who has a history or present symptoms of clinically significant disorders relating to any of the following: digestive system, cardiovascular system, endocrine system, respiratory system, blood and lymphatic, infectious disease, renal, urinary, and reproductive, system, nervous system, musculoskeletal system, immune system, otolaryngology, skin and subcutaneous tissue system, and ophthalmic system
• A volunteer who has a history of gastrointestinal surgery that may affect drug absorption (except simple appendectomy or hernia surgery) or has gastrointestinal diseases
• A volunteer who has taken drugs that induce or inhibit drug metabolizing enzymes such as barbiturates within 1 month prior to the first dose or who has taken drugs that may interfere with clinical study within 10 days prior to the first dose(Provided that, participation may be considered based on drug-drug interaction, pharmacokinetics and pharmacodynamics(such as half-life) of study drug)
• A volunteer who has participated in other clinical trials or bioequivalence studies within 6 months prior to the first dose of the study drug
• A volunteer who has participated in whole blood donation within 8 weeks prior to first dose, or apheresis donation within w weeks prior to first dose, or received blood donation within 4 weeks prior to first dose.
• A volunteer that meets any of the following conditions within 1 month prior to first dose
• Average alcohol intake(for men): \> 21 glass/week
• Average alcohol intake(for women): \> 14 glass/week (1 glass = 50ml of soju or 30ml of liquor, or 250ml of beer)
• Average cigarette smoking: \> 20 cigarettes per day.
• A volunteer that meets any of the following categories
• Volunteer who is hypersensitive to the active ingredient or other ingredients of this drug
• Patients that meet any of the following conditions
• Gastric ulcer patients possibly related to a malignant tumor
• Hepatic disorder or renal disorder patients
• Patients receiving Atazanavir

Sponsors & Collaborators

• Il-Yang Pharm. Co., Ltd.: lead

Study Sites (1)

H plus Yangji Hospital

Seoul, Gwanak-gu, 08756, South Korea

Location

Study Officials

• Jae Woo Kim, MD, PhD

  H Plus Yangji Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jung Hwa Hong, bachelor

CONTACT

+82.2.570.3777; jhhong@ilyang.co.kr

Yun Ho Kwon, bachelor

CONTACT

+82.2.570.3795; yhkwon@ilyang.co.kr

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Masking Details: In order to prevent distortion (bias) affecting test results during sample analysis, this clinical trial shall not be disclosed to analysis manager and analyst until the specimen analysis is completed.
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 8, 2022
• First Posted: November 15, 2022
• Study Start: November 30, 2024
• Primary Completion: December 10, 2024
• Study Completion: December 30, 2025
• Last Updated: March 1, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)